Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022

SELL
$7.89 - $17.88 $3,945 - $8,940
-500 Reduced 1.82%
27,000 $286,000
Q1 2022

Apr 28, 2022

SELL
$11.56 - $19.76 $3,745 - $6,402
-324 Reduced 1.16%
27,500 $447,000
Q4 2021

Jan 07, 2022

SELL
$11.18 - $15.46 $5,590 - $7,730
-500 Reduced 1.77%
27,824 $385,000
Q2 2021

Jul 22, 2021

SELL
$9.5 - $17.24 $4,750 - $8,620
-500 Reduced 1.73%
28,324 $448,000
Q1 2021

Apr 12, 2021

SELL
$7.37 - $13.61 $61,731 - $113,997
-8,376 Reduced 22.52%
28,824 $293,000
Q4 2020

Feb 11, 2021

BUY
$3.37 - $8.61 $58,975 - $150,675
17,500 Added 88.83%
37,200 $277,000
Q3 2020

Oct 28, 2020

BUY
$3.43 - $5.53 $53,165 - $85,715
15,500 Added 369.05%
19,700 $68,000
Q2 2020

Jul 20, 2020

BUY
$1.9 - $5.61 $7,980 - $23,562
4,200 New
4,200 $20,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.47B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Valeo Financial Advisors, LLC Portfolio

Follow Valeo Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valeo Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Valeo Financial Advisors, LLC with notifications on news.